Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10594684 | 0.88 | MAPT (0.45) | ALDH1A1TSHRFGFR4SMN1; SMN2MAPT | |
| SCHEMBL11055881 | 0.88 | TSHR (0.45) | ALDH1A1TSHRFGFR4SMN1; SMN2MAPT | |
| SCHEMBL31364147 | 0.81 | KDM4E (0.52) | ALDH1A1TSHRSMN1; SMN2MAPTKDM4E | |
| Octadecanoic Acid Amide SCHEMBL27917530 | 0.78 | FAAH (0.55) | TSHRKDM4E | |
| SCHEMBL24309157 | 0.78 | — | — | |
| SCHEMBL499105 | 0.78 | KDM4E (0.32) | KDM4EKDM5CPHF8KDM2A | |
| SCHEMBL223005 | 0.78 | PHF8 (0.50) | ALDH1A1TSHRMAPTKDM4EKDM5C | |
| SCHEMBL4891885 | 0.76 | — | — | |
| SCHEMBL8440530 | 0.75 | — | — | |
| SCHEMBL29158015 | 0.75 | TSHR (0.50) | ALDH1A1TSHRSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120195937-A1 | POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZAE B SACCHARIDE VACCINES | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2012-08-02 | — | — | US | claimed |
| US-20060121059-A1 | Vaccine composition | GLAXOSMTHKLINE BIOLOGICALS, S.A. (BE) | 2006-06-08 | — | — | US | claimed |
| EP-1638597-A2 | POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZA B SACCHARIDE VACCINES | GlaxoSmithKline Biologicals S.A. (BE) | 2006-03-29 | — | — | EP | claimed |
| EP-1034194-B1 | POLY(VINYLAMINE)-BASED SUPERABSORBENT GELS AND METHOD OF MANUFACTURING THE SAME | BASF AG (DE) | 2006-03-01 | — | — | EP | claimed |
| WO-2004110480-A2 | POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZA B SACCHARIDE VACCINES | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2004-12-23 | — | — | WO | claimed |
| US-6610310-B2 | Immunology response; side effect reduction | AMERICAN CYANAMID COMPANY | 2003-08-26 | — | — | US | claimed |
| US-20030021793-A1 | POLYANIONIC POLYMERS AS ADJUVANTS FOR MUCOSAL IMMUNIZATION | ZOETIS SERVICES LLC | 2003-01-30 | — | — | US | claimed |
| EP-1034194-A1 | POLY(VINYLAMINE)-BASED SUPERABSORBENT GELS AND METHOD OF MANUFACTURING THE SAME | AMCOL INTERNATIONAL CORPORATION (US) | 2000-09-13 | — | — | EP | claimed |
| US-5981689-A | FORMING A MONOMER MIXTURE COMPRISING AN N-VINYLAMIDE, 0% TO 90% BY WEIGHT OF ONE OR MORE MONOETHYLENICALLY UNSATURATED MONOMERS, AND 0% TO ABOUT 10% OF A POLYVINYL MONOMER, POLYMERIZING MONOMERS, ADDING SCAVENGING AGENT | AMCOL INTERNATIONAL CORPORATION (US) | 1999-11-09 | — | — | US | claimed |
| EP-0934077-A2 | POLYANIONIC POLYMERS AS ADJUVANTS FOR MUCOSAL IMMUNIZATION | DIMMINACO AG/SA/LTD. (CH) | 1999-08-11 | — | — | EP | claimed |
| WO-1999025745-A1 | POLY(VINYLAMINE)-BASED SUPERABSORBENT GELS AND METHOD OF MANUFACTURING THE SAME | AMCOL INTERNATIONAL CORPORATION (US) | 1999-05-27 | — | — | WO | claimed |
| WO-1998017310-A2 | POLYANIONIC POLYMERS AS ADJUVANTS FOR MUCOSAL IMMUNIZATION | DIMMINACO AG/S.A./LTD. (CH) | 1998-04-30 | — | — | WO | claimed |
| US-5516619-A | Conductive composite particles and processes for the preparation thereof | XEROX CORPORATION (US) | 1996-05-14 | — | — | US | claimed |
| US-5484681-A | Conductive composite particles and processes for the preparation thereof | XEROX CORPORATION (US) | 1996-01-16 | — | — | US | claimed |
| EP-0188110-B1 | Hydrogel-forming polymers | TR DEV LTD (GB) | 1995-09-06 | — | — | EP | claimed |
| US-5288585-A | Processes for the preparation of polymers | XEROX CORPORATION (US) | 1994-02-22 | — | — | US | claimed |
| US-4110244-A | Photochromic plastic material | AMERICAN OPTICAL CORPORATION (US) | 1978-08-29 | — | — | US | claimed |
| US-4049846-A | Photochromic plastic materials | AMERICAN OPTICAL CORPORATION (US) | 1977-09-20 | — | — | US | claimed |
| US-20260091055-A1 | Methods of Managing Traumatic Brain Injury | UNIV EMORY (US) | 2026-04-02 | — | — | US | disclosed |
| US-3939130-A | Polymers of monomers containing active methylene groups and other ethylenically unsaturated monomers | INDICON INC. (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091055-A1 | Methods of Managing Traumatic Brain Injury | SGMS2, SGMS1, S1PR2 | ALDH1A1 4310/4885TSHR 3353/4885FGFR4 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.